- Home
- DRCT vs LPCN Comparison
DRCT vs LPCN Comparison
Compare DRCT & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- LPCN
- Stock Information
- Founded
- DRCT 2018
- LPCN 1997
- Country
- DRCT United States
- LPCN United States
- Employees
- DRCT N/A
- LPCN N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- DRCT Technology
- LPCN Health Care
- Exchange
- DRCT Nasdaq
- LPCN Nasdaq
- Market Cap
- DRCT 16.7M
- LPCN 16.1M
- IPO Year
- DRCT 2022
- LPCN N/A
- Fundamental
- Price
- DRCT $0.55
- LPCN $3.00
- Analyst Decision
- DRCT Strong Buy
- LPCN Strong Buy
- Analyst Count
- DRCT 1
- LPCN 2
- Target Price
- DRCT $6.00
- LPCN $9.00
- AVG Volume (30 Days)
- DRCT 153.1K
- LPCN 29.3K
- Earning Date
- DRCT 05-06-2025
- LPCN 08-07-2025
- Dividend Yield
- DRCT N/A
- LPCN N/A
- EPS Growth
- DRCT N/A
- LPCN N/A
- EPS
- DRCT N/A
- LPCN N/A
- Revenue
- DRCT $48,170,000.00
- LPCN $3,674,834.00
- Revenue This Year
- DRCT $50.71
- LPCN N/A
- Revenue Next Year
- DRCT $26.31
- LPCN N/A
- P/E Ratio
- DRCT N/A
- LPCN N/A
- Revenue Growth
- DRCT N/A
- LPCN N/A
- 52 Week Low
- DRCT $0.44
- LPCN $2.68
- 52 Week High
- DRCT $6.59
- LPCN $7.61
- Technical
- Relative Strength Index (RSI)
- DRCT 44.03
- LPCN 40.07
- Support Level
- DRCT $0.53
- LPCN $3.10
- Resistance Level
- DRCT $0.63
- LPCN $3.39
- Average True Range (ATR)
- DRCT 0.05
- LPCN 0.18
- MACD
- DRCT -0.00
- LPCN -0.00
- Stochastic Oscillator
- DRCT 12.67
- LPCN 0.00
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.